Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 20, 2023
Deals
BioNTech sees differentiation in OncoC4’s CTLA-4, commits $200M up front
German biotech to explore combinations with molecule engineered to affect tumor microenvironment without triggering unwanted autoimmune effects
BioCentury | Jun 24, 2022
Emerging Company Profile
DEM BioPharma: exploring ‘don’t eat me’ white space beyond CD47
Backed with $70M, the start-up unites Trillium alumni with academics to discover more phagocytosis targets for cancer
BioCentury | Jun 6, 2022
Deals
Sale of programs to J&J leaves Yumanity as shell for Kineta reverse merger
Combined company to advance Seattle biotech’s cancer programs as Yumanity’s eight-year history in neurodegeneration comes to a close
BioCentury | May 10, 2022
Emerging Company Profile
Pheast: Forty Seven founders reunite for precision macrophage combos
Backed by Catalio and Arch, start-up from Forty Seven founders aims to target patient-specific ‘don’t eat me’ signals beyond CD47
BioCentury | May 4, 2022
Finance
Newcomer Catalio builds momentum with $381M biotech venture fund
Firm’s model attracts top academics for company creation
BioCentury | Apr 27, 2022
Deals
April 26 Quick Takes: CD24 will be new focus of Forty Seven founders as Stanford spinout Pheast debuts
Plus Nkarta follows breakthrough data with $200M raise, and updates from Epitopea, Forcefield and
BioCentury | Apr 15, 2021
Product Development
Merck’s COVID-19 arsenal continues to dwindle as pharma scraps fusion protein from OncoImmune takeout
Merck’s roster of COVID-19 countermeasures gained via deals continued to shrink Thursday, when the pharma said it would terminate one therapeutic program and end development of another in
BioCentury | Apr 15, 2021
Deals
Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making
Merck, WuXi BD alum Tong Zhang readies his tool kit to partner assets with roots in China’s hospitals
BioCentury | Jan 25, 2021
Product Development
Merck shifts COVID-19 focus to therapeutics after discontinuing vaccines
With Merck’s two COVID-19 vaccines falling short of the mark, the U.S. pharma is shifting its focus to late-stage readouts this half for therapeutics to treat the coronavirus. Merck & Co.
Items per page:
1 - 10 of 29